Navigation Links
Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
Date:10/3/2007

SAN MATEO, Calif., Oct. 3 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing anti-inflammatory therapeutics for chronic and acute inflammatory diseases, announced today the completion of enrollment and patient dosing in its Phase II clinical study of its lead compound, A-002 for stable coronary artery disease. Data analysis is scheduled to be completed by the end of the year.

"We are pleased with the rapid enrollment of this study and look forward to reporting the results later this year," said Colin Hislop, M.D., Senior Vice President Clinical Development at Anthera Pharmaceuticals. "Previously reported results have been promising and we expect the results of our ongoing evaluation will help guide Phase III clinical trial design."

A-002 Clinical Trial Protocol

The PLASMA trial (Phospholipase Levels And Serological Markers of Atherosclerosis) is a multi-center, randomized, double-blind, placebo-controlled trial that enrolled approximately 400 patients with stable coronary heart disease. Subjects were randomized to receive four doses of A-002 or standard of care for up to eight weeks. The study was designed to investigate the safety and the efficacy of A-002 (a potent inhibitor of the human enzymes known as secretory phospholipase A2) on dyslipidemia (primarily Low Density Lipoprotein Cholesterol "LDL-C") and systemic inflammation (as measured by levels of C-Reactive Protein "CRP") in patients with stable coronary heart disease. Elevated levels of sPLA2 have been implicated in abnormal lipid metabolism, atherogenesis and vascular inflammation. The Company is scheduled to meet with the Food and Drug Administration in the fourth quarter for an end-of-Phase II meeting to obtain concurrence on the design of the Phase III program.

A-002 Once Daily Clinical Trial

Based on preliminary data from the PLASMA Phase II clinical trial, Anthera has initiated a follow up clinical study investigat
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... -- According to Kalorama Information, electronic medical records (EMR) ... in healthcare a reality, and this a factor that ... Recovery and Reinvestment Act, the U.S. government dedicated $20.6 ... will start applying soon for use of paper records.  ... of the EMR industry, EMR 2014: The Market ...
(Date:8/19/2014)... 2014  Cardiva Medical, Inc. announced today that it ... million Series 3 private equity financing and a $12.5 ... will use the proceeds of the Series 3 private ... for its VASCADE® Vascular Closure System in ... in Series 3 private equity financing was a new ...
(Date:8/19/2014)... , Aug. 19, 2014  Regeneron Pharmaceuticals, Inc. (NASDAQ: ... conferences: , Sanofi and Regeneron will host an IR ... on Tuesday, September 2, 2014 , Baird 2014 ... September 3, 2014 , Citi,s 9 th ... Thursday, September 4, 2014 , Morgan Stanley Global ...
Breaking Medicine Technology:Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2
(Date:8/20/2014)... (PRWEB) August 20, 2014 BuyCheapTicketsToEvents.com ... a wide selection of tickets to many events. Cheap NHL ... will begin in September. , Hockey fans are enthusiastic about ... obtain tickets for games. Now is the time to acquire ... begin in mere months. There will be a great deal ...
(Date:8/20/2014)... people grow older, they often have difficulty falling asleep ... in the morning. In individuals with Alzheimer,s disease, this ... especially pronounced, often leading to nighttime confusion and wandering. ... Israel Deaconess Medical Center (BIDMC) and the University of ... more fragmented with age. Reported online today in the ...
(Date:8/20/2014)... Mixberry Media announced today its new ... create a new source of revenue. , The innovative ... to a narration of their favorite news and articles ... Users can now multitask: read/write email, drink coffee, ... content. , Mixberry Media’s service converts news ...
(Date:8/20/2014)... August 20, 2014 Riverside Health System ... , who joined its Warsaw Medical Arts team earlier ... in Family Medicine, is accepting new patients. , Dameron, ... Medicine, completed his residency at the Mountain Area Health ... Virginia. , “I really like the rural aspect of ...
(Date:8/19/2014)... 20, 2014 As moms and dads prepare ... to return to the normal routine of dropping their little ... Kristen Yarker, MSc, RD encourages them to use the ... snack time. , Yarker explains, “Kids have small tummies, ... of giving them junk food handouts, use snack time as ...
Breaking Medicine News(10 mins):Health News:2014 NHL Preseason Tickets Are Among Top Selling Seats at Trusted Provider BuyCheapTicketsToEvents.com 2Health News:Research helps explain why elderly have trouble sleeping 2Health News:Research helps explain why elderly have trouble sleeping 3Health News:Mixberry Media, First To Offer Article Voice Narration with Integrated Audio Advertising 2Health News:Riverside Warsaw Medical Arts’ Dr. William Dameron Accepting New Patients 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 3
... FirmsPHILADELPHIA, Jan. 15 /PRNewswire/ -- Michael ... Centocor, Inc., an operating company of Johnson & ... public relations consultancy, Pitch360 Incorporated ( www.pitch360inc.com ). ... issues management consultancy that leverages its vast pharmaceutical ...
... aging causes broken bones to heal slowly, or not at ... Journal of Bone and Mineral Research . The research team ... of treatments designed to "rescue" healing capability lost to aging. ... healing keeps the two sides of a fractured bone from ...
... Enterprises Ltd. ("Beeston") (OTC-BB:BESE) a resource base company ... mineral properties, announced that its Board of Directors ... of its full media campaign. MicroCap Management has ... a launch pad for Beeston,s present and future ...
... Area Treatments Twice as Fast and Improves Patient Treatment ... SLTM ) today announced the launch of ... system for faster, more comfortable body shaping, contouring and ... of traditional Thermage tips, Body Tip 16.0 cuts body ...
... WINSTON-SALEM, N.C., Jan. 15 For consumers, the Internet,offers ... vacations; however,when it comes to finding the best doctor, ... days, there are Web sites that offer ratings on,everyone ... picking,the best restaurants and hotels in town are getting ...
... Outlines Steps Taken to Reduce Expenses in Light ... Mass., Jan. 15 Cynosure, Inc. (NASDAQ: ... of a broad array of light-based aesthetic treatment ... fourth quarter ended December 31, 2008.Cynosure expects to ...
Cached Medicine News:Health News:Former Johnson & Johnson Executive Gives Big Voice to Small Companies 2Health News:Researchers detail how aging undermines bone healing 2Health News:Researchers detail how aging undermines bone healing 3Health News:Researchers detail how aging undermines bone healing 4Health News:Beeston Retains MicroCap Management, LLC as Its Lead Corporate Communications and Broker Relations Firm 2Health News:Beeston Retains MicroCap Management, LLC as Its Lead Corporate Communications and Broker Relations Firm 3Health News:Video: Solta Medical Introduces Advanced Thermage Body Tip 16.0 for Faster Body Shaping and Contouring Treatments 2Health News:Video: Solta Medical Introduces Advanced Thermage Body Tip 16.0 for Faster Body Shaping and Contouring Treatments 3Health News:DrScore.com Says: Know Your Source When Going Online To Review Your Doctor's Rating 2Health News:DrScore.com Says: Know Your Source When Going Online To Review Your Doctor's Rating 3Health News:Cynosure Provides Preliminary Financial Results for the Fourth Quarter of 2008 2Health News:Cynosure Provides Preliminary Financial Results for the Fourth Quarter of 2008 3Health News:Cynosure Provides Preliminary Financial Results for the Fourth Quarter of 2008 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: